Caribou Biosciences, Inc. (NASDAQ:CRBU – Get Free Report) CEO Rachel E. Haurwitz acquired 20,000 shares of the business’s stock in a transaction that occurred on Friday, March 14th. The shares were purchased at an average cost of $1.02 per share, for a total transaction of $20,400.00. Following the completion of the transaction, the chief executive officer now directly owns 3,369,395 shares in the company, valued at $3,436,782.90. The trade was a 0.60 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
Caribou Biosciences Price Performance
Shares of CRBU stock traded up $0.01 during mid-day trading on Monday, hitting $1.02. The company had a trading volume of 83,205 shares, compared to its average volume of 1,603,439. Caribou Biosciences, Inc. has a 52-week low of $0.98 and a 52-week high of $5.77. The stock’s 50 day moving average price is $1.37 and its 200-day moving average price is $1.77. The company has a market capitalization of $94.40 million, a P/E ratio of -0.62 and a beta of 2.34.
Caribou Biosciences (NASDAQ:CRBU – Get Free Report) last released its earnings results on Monday, March 10th. The company reported ($0.39) EPS for the quarter, topping the consensus estimate of ($0.40) by $0.01. The firm had revenue of $2.08 million for the quarter, compared to the consensus estimate of $2.11 million. Caribou Biosciences had a negative net margin of 1,290.81% and a negative return on equity of 45.46%. On average, equities research analysts expect that Caribou Biosciences, Inc. will post -1.64 earnings per share for the current year.
Institutional Investors Weigh In On Caribou Biosciences
Wall Street Analyst Weigh In
Several equities analysts have issued reports on the stock. Citigroup lowered their target price on shares of Caribou Biosciences from $30.00 to $6.00 and set a “buy” rating on the stock in a research note on Tuesday, November 26th. Bank of America lowered their price objective on shares of Caribou Biosciences from $13.00 to $11.00 and set a “buy” rating on the stock in a research note on Tuesday, January 7th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Caribou Biosciences has a consensus rating of “Buy” and an average target price of $10.33.
Check Out Our Latest Stock Analysis on CRBU
About Caribou Biosciences
Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.
Featured Stories
- Five stocks we like better than Caribou Biosciences
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Consumers Are Cutting Back, But These 3 Stocks Will Stay Strong
- Bank Stocks – Best Bank Stocks to Invest In
- Disney Stock: 4 Key Metrics Validating Its Comeback
- How to Calculate Stock Profit
- Resilient Investing: 3 Stocks Built to Weather Market Volatility
Receive News & Ratings for Caribou Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caribou Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.